Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives
Authors
Keywords
-
Journal
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-09
DOI
10.1007/s11154-020-09551-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review
- (2019) Yong Wang et al. World Neurosurgery
- Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
- (2019) Aida Karachi et al. NEURO-ONCOLOGY
- Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
- (2019) Sabrina Heynckes et al. BMC CANCER
- Surgery, octreotide, temozolomide, bevacizumab, radiotherapy and pegvisomant treatment of an AIP mutation positive child
- (2019) Pinaki Dutta et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series
- (2019) Rayan Alsuwaigh et al. Journal for ImmunoTherapy of Cancer
- Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging
- (2019) Hye Rim Cho et al. Scientific Reports
- Aggressive pituitary tumours and carcinomas: two sides of the same coin?
- (2018) Jacqueline Trouillas et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
- (2018) Ann McCormack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
- (2018) Conor E. Steuer et al. JOURNAL OF CLINICAL ONCOLOGY
- Premature Physiologic Aging as a Paradigm for Understanding Increased Risk of Adverse Health Across the Lifespan of Survivors of Childhood Cancer
- (2018) Kirsten K. Ness et al. JOURNAL OF CLINICAL ONCOLOGY
- The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy
- (2018) Peng-fei Wang et al. JOURNAL OF NEURO-ONCOLOGY
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
- (2018) Song Ee Park et al. Journal of Thoracic Oncology
- Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response
- (2018) Sabine Hombach-Klonisch et al. PHARMACOLOGY & THERAPEUTICS
- MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals
- (2018) Alexander S. G. Micko et al. Pituitary
- Early recognition and initiation of temozolomide chemotherapy for refractory, invasive pituitary macroprolactinoma with long-term sustained remission: a case report
- (2018) Garni Barkhoudarian et al. World Neurosurgery
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
- (2018) Luis V. Syro et al. Frontiers in Endocrinology
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
- (2018) Shabierjiang JIAPAER et al. NEUROLOGIA MEDICO-CHIRURGICA
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Long-Term Survival After Transformation of an Adrenocorticotropic Hormone–Secreting Pituitary Macroadenoma to a Silent Corticotroph Pituitary Carcinoma
- (2018) Lauren E. Rotman et al. World Neurosurgery
- Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas
- (2017) Hélène Lasolle et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort
- (2017) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection
- (2017) Waseem Touma et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
- (2017) Gustavo Schvartsman et al. LUNG CANCER
- Detection of programmed death ligand 1 protein and CD8+ lymphocyte infiltration in plurihormonal pituitary adenomas
- (2017) Pengfei Wang et al. MEDICINE
- MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas
- (2017) Alexander S. G. Micko et al. Pituitary
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Excellent response to chemotherapy post immunotherapy
- (2017) Ashish D. Dwary et al. Oncotarget
- MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors
- (2016) J Cros et al. ENDOCRINE-RELATED CANCER
- DNA repair mechanisms and their clinical impact in glioblastoma
- (2016) Hélène Erasimus et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Clonal evolution of glioblastoma under therapy
- (2016) Jiguang Wang et al. NATURE GENETICS
- Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma
- (2016) Carlos Kamiya-Matsuoka et al. Pituitary
- Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
- (2016) D. Mathios et al. Science Translational Medicine
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
- (2015) M. Weller et al. CLINICAL CANCER RESEARCH
- Deficient mismatch repair: Read all about it (Review)
- (2015) SUSAN RICHMAN INTERNATIONAL JOURNAL OF ONCOLOGY
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
- (2015) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas
- (2015) Marco Losa et al. JOURNAL OF NEURO-ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment
- (2015) Mariana Campderá et al. Pituitary
- Novel MSH6 Mutations in Treatment-Naive Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation
- (2014) S. A. Nguyen et al. CLINICAL CANCER RESEARCH
- Multiple Cerebral Hemorrhagic Foci From Metastases During Temozolomide Treatment in a Patient With Corticotroph Pituitary Carcinoma
- (2014) Marco Mendola et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors
- (2013) Toshio Hirohata et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary hematological malignancies associated with temozolomide in patients with glioma
- (2013) H. Momota et al. NEURO-ONCOLOGY
- High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM)
- (2013) Brad E. Zacharia et al. NEUROSURGERY
- Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment
- (2012) Melanie Philippon et al. ANNALES D ENDOCRINOLOGIE
- Temozolomide in the management of dopamine agonist-resistant prolactinomas
- (2012) B. C. Whitelaw et al. CLINICAL ENDOCRINOLOGY
- Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
- (2011) Ann I. McCormack et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients
- (2011) Sameer Agnihotri et al. JOURNAL OF CLINICAL INVESTIGATION
- MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas
- (2011) Fateme Salehi et al. JOURNAL OF NEURO-ONCOLOGY
- A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report
- (2011) Mineko Murakami et al. NEUROSURGERY
- Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature
- (2011) A. K. Annamalai et al. Pituitary
- A Rare Case of Aplastic Anemia Caused by Temozolomide
- (2011) Benjamin J. George et al. SOUTHERN MEDICAL JOURNAL
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- Dose-dense temozolomide regimens
- (2010) Bart Neyns et al. CANCER
- Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression
- (2010) Zachary M. Bush et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
- (2010) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MGMT immunoexpression in aggressive pituitary adenoma and carcinoma
- (2010) Queenie Lau et al. Pituitary
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
- (2009) S. Yip et al. CLINICAL CANCER RESEARCH
- Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy
- (2009) C Hagen et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
- (2008) M. H. Kulke et al. CLINICAL CANCER RESEARCH
- Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours
- (2008) Ann I. McCormack et al. CLINICAL ENDOCRINOLOGY
- Non-Hodgkin's Lymphoma in Patients With Glioma Treated With Temozolomide
- (2008) Bart Neyns et al. JOURNAL OF CLINICAL ONCOLOGY
- Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature
- (2008) Agatha A. van der Klaauw et al. Pituitary
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started